AbbVie Inc.
Guidance Including the Impact of Acquired IPR&D and Milestones Expense
(Unaudited)
(in millions, except per share data) | Quarter Ended September 30, 2023 | Full-Year Ended December 31, 2023 | |||||||||||||||||||||||||||||||||
Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | ||||||||||||||||||||||||||||||||
Low | High | Low | High | ||||||||||||||||||||||||||||||||
Previously announced guidance excluding Q3 2023 acquired IPR&D and milestones expense | $ | — | $ | 2.80 | $ | 2.90 | $ | 430 | $ | 10.90 | $ | 11.10 | |||||||||||||||||||||||
Q3 2023 acquired IPR&D and milestones expense | 66 | (0.04) | (0.04) | 66 | (0.04) | (0.04) | |||||||||||||||||||||||||||||
Guidance including Q3 2023 acquired IPR&D and milestones expensea | $ | 66 | $ | 2.76 | $ | 2.86 | $ | 496 | $ | 10.86 | $ | 11.06 |
a The Company's 2023 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the third quarter of 2023, as both cannot be reliably forecasted.
1